LL-37 is a 37-residue peptide derived from the C-terminus of the human cathelicidin protein hCAP18. It is a widely studied model antimicrobial and host-defense peptide.
LL-37 is the only cathelicidin-derived antimicrobial peptide identified in humans and is used as a reference compound in innate-immunity, antimicrobial, and membrane-interaction research.
In laboratory models, LL-37 has been investigated for antimicrobial activity against bacteria and biofilms, immunomodulatory signaling, and roles in wound-healing and angiogenesis research models. These observations are limited to laboratory and preclinical research settings and are not statements about outcomes in humans.
Supplied as a lyophilized powder. Store lyophilized material at -20°C. Reconstitution with bacteriostatic or sterile water is common for laboratory handling; keep any reconstituted solution refrigerated and use it within the timeframe appropriate to the researcher’s protocol.
Purity is determined by HPLC and identity is confirmed by mass spectrometry. Each batch ships with a batch-specific certificate of analysis from an independent third-party laboratory; refer to the COA for lot-specific measured values. Endotoxin and sterility testing are not performed unless explicitly stated.
LL-37 is a fragment of the human cathelicidin antimicrobial peptide hCAP18, used as a model antimicrobial and innate-immunity reference compound in the laboratory.
Store the lyophilized powder at -20°C. Handle and store any reconstituted solution per your laboratory protocol.
Purity by HPLC and identity by mass spectrometry, batch-specific, from an independent third-party lab. Refer to the COA for the measured purity. Endotoxin and sterility are not tested unless stated.
No. It is sold strictly for in-vitro laboratory research and is not for human or veterinary use.